| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $45.2M | +12.7% | +1.1% |
| SG&A Expense | $11.6M | -1.3% | +9.3% |
| Operating Income | -$56.9M | -35.7% | -2.7% |
| Pre-tax Income | -$11.2M | +69.5% | +83.8% |
| Income Tax | $0 | — | -100.0% |
| Net Income | -$11.2M | +69.5% | +83.8% |
| EPS (Diluted) | -$1.24 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $64.9M | -20.5% | -9.3% |
| Current Assets | $504.6M | -6.4% | +19.8% |
| Total Assets | $504.6M | -6.4% | +19.8% |
| Current Liabilities | $46.3M | -44.3% | -19.6% |
| Total Liabilities | $49.5M | -40.4% | -47.2% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$124.7M | — | — |
| Investing Cash Flow | $103.9M | — | — |
| Financing Cash Flow | -$3.8M | — | — |
| — |
| +8.8% |
| $455.1M |
| -0.1% |
| +39.0% |